Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Kiadis Pharma obtains U.S. patent for cell-based therapy for GVHD
Kiadis Pharma has secured a U.S. patent for its cell-based blood therapy ATIR. The patent covers the use of the treatment to reduce the risk of graft-versus-host disease due to allogeneic stem cell transplant.
Or we can send an email on your behalf